Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0QIAGC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Anti-KIT NEG024?CX1-1-DM1
|
|||||
| Synonyms |
Anti-KIT-NEG024?CX1-1-DM1
Click to Show/Hide
|
|||||
| Organization |
Novartis AG
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 3 Indication(s)
Acute myeloid leukaemia [ICD11:2A60]
Investigative
Melanoma [ICD11:2C30]
Investigative
Small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3-4
|
|||||
| Antibody Name |
Anti-KIT mAb NEG024
|
Antibody Info | ||||
| Antigen Name |
Mast/stem cell growth factor receptor Kit (KIT)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM1
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
2,5-Dioxopyrrolidin-1-yl 17-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5,8,11,14-tetraazaheptadecan-1-oate (CX1-1)
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.